Home/Filings/4/0001127602-22-004986
4//SEC Filing

Vounatsos Michel 4

Accession 0001127602-22-004986

CIK 0000875045other

Filed

Feb 14, 7:00 PM ET

Accepted

Feb 15, 4:12 PM ET

Size

19.7 KB

Accession

0001127602-22-004986

Insider Transaction Report

Form 4
Period: 2022-02-12
Vounatsos Michel
EVP & Chief Commercial Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2022-02-12+4,39570,465.188 total
  • Exercise/Conversion

    Restricted Stock Unit

    2022-02-124,39520,727 total
    Exercise: $0.00Exp: 2023-02-12Common Stock (4,395 underlying)
  • Exercise/Conversion

    Common Stock

    2022-02-12+4,32167,987.188 total
  • Tax Payment

    Common Stock

    2022-02-12$214.59/sh1,950$418,45168,515.188 total
  • Tax Payment

    Common Stock

    2022-02-12$214.59/sh4,699$1,008,35863,816.188 total
  • Other

    Restricted Stock Unit

    2022-02-128,2050 total
    Exercise: $0.00Exp: 2022-02-12Common Stock (8,205 underlying)
  • Tax Payment

    Common Stock

    2022-02-12$214.59/sh1,917$411,36966,070.188 total
  • Exercise/Conversion

    Restricted Stock Unit

    2022-02-124,3218,205 total
    Exercise: $0.00Exp: 2022-02-12Common Stock (4,321 underlying)
  • Other

    Restricted Stock Unit

    2022-02-128,16312,564 total
    Exercise: $0.00Exp: 2023-02-12Common Stock (8,163 underlying)
Footnotes (3)
  • [F1]Represents shares withheld to satisfy the withholding tax liability due upon vesting of shares, as previously disclosed by reporting person on January 21, 2022.
  • [F2]The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).
  • [F3]This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

Issuer

BIOGEN INC.

CIK 0000875045

Entity typeother

Related Parties

1
  • filerCIK 0001672709

Filing Metadata

Form type
4
Filed
Feb 14, 7:00 PM ET
Accepted
Feb 15, 4:12 PM ET
Size
19.7 KB